One of the major challenges of measurable residual disease (MRD) utilization is the standardization of its measurement and reporting. Here,…
Browsing: Acute Myelogenous Leukemia
A Phase I trial (NCT02074839) investigating the IDH1 inhibitor ivosidenib has demonstrated encouraging results in relapsed/refractory acute myeloid leukemia (AML).…
Despite recent advancements in CAR T-cell therapy for the treatment of acute myeloid leukemia (AML), standard chemotherapy is still the…
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses the early trials that are currently underway to…
Acute myeloid leukemia (AML) is a highly heterogenous disease, and the specific mutations that are present in the patient play…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Andrew Wei,…
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses clinical trials investigating the effect of BH3 mimetic…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Marion Subklewe,…
Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, discusses several clinical trials in acute myeloid leukemia (AML) that are…
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the new and exciting clinical trials…
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the rationale behind determining the most suitable…
Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the…
Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for…
The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are…
Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic…
Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this…
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the mechanisms of resistance to targeted…
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis,…
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains the mechanisms of isocitrate dehydrogenase (IDH)…
Traditionally, the standard therapy for the management of acute myeloid leukemia (AML) in elderly patients has been low-dose cytarabine, but…
Minimal residual disease (MRD) is a highly important prognostic indicator used to determine treatment efficacy in acute myeloid leukemia (AML)…
Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different…
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses how his team is carrying out treatment…
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains how the lack of novel drugs for…
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that…
Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser,…
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the research carried out by some of his former…
Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell…
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of…
Amer M Zeidan, MBBS, explains 4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to…